MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Aerobic Exercise in Non-Exercisers with Advanced Parkinson’s Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study

    S. Aslam, M. Olson, S. Felson, F. Ponce, H. Shill (Aurora, USA)

    Objective: To assess the feasibility of an aerobic exercise regimen in those with advanced PD and DBS. Background: Aerobic exercise is known to have beneficial…
  • 2024 International Congress

    AAV-mediated gene therapy for GBA-PD

    S. Ayloo, J. Ryu, S. Chou, C. Miller, L. Blatnik, E. Wischhof, J. Bu, W. Mccarty, L. Guo, S. Nass, C. O'Riordan, B. Elmer, C. Mueller, S. Ramachandran (Waltham, USA)

    Objective: Development of a gene therapy-based drug for treatment of GBA-PD, a genetic subtype of Parkinson’s disease Background: Mutations in GBA1, the gene encoding glucocerebrosidase…
  • 2024 International Congress

    Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage

    D. Kremens, F. Amjad, S. Thakkar, B. Naderi, D. Martins, J. Rocha, G. Banisadr, S. Fisher (Wynnewood, USA)

    Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…
  • 2024 International Congress

    Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

    AA. Vanderplas (Leiderdorp, Netherlands)

    Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…
  • 2024 International Congress

    Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease

    R. Hughes, O. Bandmann, L. Ferraiuolo, H. Mortiboys (Sheffield, United Kingdom)

    Objective: To undertake a repurposing drug screen for Parkinson’s disease (PD) and further investigate the mechanism of action of top hits. To assess, in vivo,…
  • 2024 International Congress

    Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease

    G. Agyeah, J. Ghelfi, L. Gallucci, A. Rakovic, P. Antony, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

    Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…
  • 2024 International Congress

    Age- and Sex-Associated Changes in the Behavior of Neuronal Mitochondria During Healthy Aging

    E. Klinman, A. Yoo (St Louis, USA)

    Objective: To determine age-associated changes in the size, density, movement, and dynamics of mitochondria as a function of sex, using microRNA-induced neurons derived from primary…
  • 2024 International Congress

    Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson’s Disease

    ST. Tsai, MK. Lu, CH. Tsai, Y. Aoh, ZL. Lai, YY. Hsu, DS. Chao, PR. Hsueh (Taichung, Taiwan)

    Objective: To compare the gut microbiota in patients with Parkinson’s disease (PD) and healthy controls and predict the functional pathways associated with these differences. Background:…
  • 2024 International Congress

    Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

    C. Henchcliffe, H. Sarva, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (Orange, USA)

    Objective: To describe the effects of bemdaneprocel on motor and non-motor outcomes in participants with Parkinson’s disease (PD) up to 24 months post transplantation (12…
  • 2024 International Congress

    A Curious Case of Copper de-Compensation

    D. Tang, CH. Tan, SF. Woo, D. Soon, J. Tan (Singapore, Singapore)

    Objective: To describe the investigation and management of a patient with Wilson’s disease who experienced late-onset neurological deterioration despite continued treatment. Background: Wilson’s disease is…
  • « Previous Page
  • 1
  • …
  • 105
  • 106
  • 107
  • 108
  • 109
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley